Popular terms

[SEARCH]

Analogue topics
Carbon Dioxide
Amino Acid
Radio Signal
Inorganic Compounds
Hydrogen Production From Water
Electrolysis
Semiconductor
High Energy
Semiconductor Material
Transmitter
Synchronization
Concurrent
Surfactant
Hyperglycemia
Pharmaceutically Acceptable Salt

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Analogue patents



      
           
This page is updated frequently with new Analogue-related patent applications. Subscribe to the Analogue RSS feed to automatically get the update: related Analogue RSS feeds. RSS updates for this page: Analogue RSS RSS



Date/App# patent app List of recent Analogue-related patents
08/20/15
20150233961 
 Analogue amplification device intended in particular for a laser anemometer patent thumbnailAnalogue amplification device intended in particular for a laser anemometer
An analogue amplification device comprises a first stage with a common base or gate transistor that receives the modulated input current on its emitter or its source and the output signal of this first stage corresponds to the signal of the collector, a second stage formed by a follower amplifier comprising a transistor with a common collector or drain setup, a third stage that comprises a transistor with a common emitter setup, and a fourth stage that is an amplifying stage with means allowing the realization of, on the one hand, an amplification, and on the other hand, a matching of impedance. The device can be applied to a laser anemometer with optical retro-injection..
Institut National Polytechnique De Toulouse


08/20/15
20150232574 
 Predictive marker for topoisomerase i inhibitors patent thumbnailPredictive marker for topoisomerase i inhibitors
The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase i (topo i) inhibitors in the treatment of cancers.
Boston Medical Center Corporation


08/20/15
20150232527 
 Glucagon-like peptide-1 analogue monomer and dimer, preparation method therefor and application thereof patent thumbnailGlucagon-like peptide-1 analogue monomer and dimer, preparation method therefor and application thereof
Provided are a glucagon-like peptide-1 (glp-1) analogue monomer and dimmer, a preparation method thereof, and an application thereof. The glp-1 analogue monomer comprises one cysteine; and the dimer is formed by two monomer molecules connected via an intermolecular disulfide bond formed by the cysteine.
Tianjin Institute Of Pharmaceutical Research


08/20/15
20150232519 
 Mutant apoprotein of photoprotein with low calcium sensitivity patent thumbnailMutant apoprotein of photoprotein with low calcium sensitivity
Calcium-binding photoproteins showing the luminescence pattern with a slow decay of are desired. The invention provides a mutant apoprotein comprising an amino acid sequence wherein the 23rd to 34th amino acids in the amino acid sequence of seq id no: 2 are substituted with an amino acid represented by formula i below: xaa23-xaa24-xaa25-xaa26-xaa27-xaa28-xaa29-xaa30-xaa31-xaa32-xaa33-xaa 34; having a function to bind to the peroxide of coelenterazine or the peroxide of a coelenterazine analogue to form a photoprotein capable of emitting light under the action of calcium ions; and, having a half decay time of the luminescence emitted by binding of the photoprotein to calcium ions being not less than 2 seconds..
Jnc Corporation


08/20/15
20150232502 
 Novel neisseria gonorrhoeae therapeutic based on cmp-nonulosonate sugars patent thumbnailNovel neisseria gonorrhoeae therapeutic based on cmp-nonulosonate sugars
N. Gonorrhoeae has become resistant to almost every conventional antibiotic.
National Research Council Of Canada


08/20/15
20150231261 
 Pharmaceutical compositions comprising nebivolol or a nebivolol analogue patent thumbnailPharmaceutical compositions comprising nebivolol or a nebivolol analogue
The present application provides pharmaceutical compositions comprising as the active medicinal ingredient nebivolol, a nebivolol analog or a pharmaceutically acceptable acid addition salt thereof and a wetting agent. The invention also relates to methods of preparing and using said compositions..
Mylan Pharmaceuticals Ulc


08/20/15
20150231190 
 Compositions comprising siraitia grosvenori extracts and methods for the treatment of infection patent thumbnailCompositions comprising siraitia grosvenori extracts and methods for the treatment of infection
A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of siraitia grosvenori swingle and administering the composition to the subject. The fruit from which the extract is derived is luo han guo.
Cascade Estates Limited


08/20/15
20150231171 
 Nylon-3 co-polymers and synthetic lung surfactant compositions containing same patent thumbnailNylon-3 co-polymers and synthetic lung surfactant compositions containing same
Non-natural oligomers have recently shown promise as functional analogues of lung surfactant proteins b and c (sp-b and sp-c), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of sp-b and sp-c has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes.
Wisconsin Alumni Research Foundation


08/20/15
20150231143 
 Heteroaryl derivatives as alpha7 nachr modulators patent thumbnailHeteroaryl derivatives as alpha7 nachr modulators
Wherein z, m and r1-r6 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the α7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as alzheimer's disease, mild cognitive impairment, senile dementia, and the like..

08/13/15
20150230324 
 Radiation signal processing device, radiation imaging system, and radiation signal processing method patent thumbnailRadiation signal processing device, radiation imaging system, and radiation signal processing method
A radiation signal processing device including: a reception section that receives as a digital signal a signal representing a detection result from a radiation imaging device that captures an image according to irradiated radiation, and that detects a radiation irradiation amount and outputs the signal representing the detection result; and a conversion section that converts the digital signal representing the detection result received by the reception section into an analogue signal recognizable by a radiation irradiation device that irradiates radiation onto the radiation imaging device and stops radiation irradiation in cases in which radiation has reached a specific irradiation amount.. .
Fujifilm Corporation


08/13/15
20150225690 

Yeast mutant and yeast extract


A natural yeast extract which is rich in glutamic acid and therefore has an impact at first taste. Further, provided is a yeast extract which is also rich in 5′-guanylic acid or 5′-inosinic acid and therefore has strong umami.
Kohjin Co., Ltd.


08/13/15
20150225499 

Molecularly imprinted polymers


The present invention refers to new classes of polymerisable monomers targeting biotin, a biotin derivative, a biotin analogue or a biotinylated molecule and related structures, as well as molecularly imprinted polymers obtainable by polymerisation of at least one of these monomers and at least one cross-linking monomer in the presence of a suitable template molecule. The obtained polymers may be used for separation of biotin and related small molecules, together with larger biotinylated molecules of biological origin, e.g.
The University Of Kent


08/13/15
20150225454 

Tetrabranched peptides and analogues as a new class of antimicrobials and their preparation thereof


An isolated peptide tetramer includes the formula [(rgrkvvrr)2k]2kk and its derivatives thereof. The derivatives may include at least one amino acid substitution, at least one amino acid deletion, a rearrangement of the peptide monomer and/or at least one non-proteogenic amino acid modification in at least one peptide monomer.
Agency For Science, Technology And Research


08/13/15
20150225426 

Anti-cancer agents and methods of use


An anti-cancer agent includes au(i) purinyl, indolyl, or azaindolyl analogues encapsulated in sterically hindered phosphine ligands.. .
Case Western Reserve University


08/06/15
20150222382 

Ofdm signal processing method and apparatus


The invention provides a reception method and apparatus which provides a series of frequency shifts and filtering operations to sideband signals (lower, upper, and middle), to enable detection if the central part of a signal is analogue or digital, and to enable effective co-channel interference compensation. The invention enables (h)iboc signals for example to be processed with a narrower bandwidth and therefore a lower processing clock speed and complexity is made possible compared to the conventional (h)iboc-signal processing approach..
Nxp B.v.


08/06/15
20150218223 

Somatostatin analogues


The invention provides cyclo[{4-(nh2—c2h4—nh—co—o—)pro}-phg-dtrp-lys-tyr(4-benzyl)-phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.. .
Novartis Ag


08/06/15
20150218202 

Non-enzymatic synthesis of o-acetyl-adp-ribose and analogues thereof


Provided herein is a simple, one-step, non-enzymatic synthesis of o-acetyl-adp-ribose (oaadpr) from nad and sodium acetate in acetic acid. The extension of this reaction to other carboxylic acids, demonstrates that the reaction between nad, and nad analogs produces mixtures of the corresponding 2′- and 3′-carboxylic esters.

08/06/15
20150218199 

Hydroxylated krn7000 analogue and use thereof


Wherein r1 is a hydrogen atom or a hydroxyl group; two r2 are the same or different and each is a hydrogen atom or a hydroxyl group; r3 is a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and r4 is a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof..

08/06/15
20150216981 

Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives


Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed.. .
Sanofi


08/06/15
20150216942 

Nanoparticle-insulin and insulin analogue compositions


The present invention relates to insulin- and insulin analogue-carrying nanoparticles formulated together with or for use with free insulin or with an insulin analogue, such as a rapidly-acting insulin analogue. The compositions of the present invention find use in medicine, particularly in glycemic control, e.g.
Midatech Limited


08/06/15
20150216941 

Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives


Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed.. .
Sanofi


08/06/15
20150216481 

System and acquisition of biopotential signals with motion artifact reduction in real time operation


A biopotential signal acquisition system comprising an analogue readout unit configured to receive an analogue biopotential signal and to extract an analogue measured biopotential signal and an analogue reference signal, and an adc unit configured to provide a digital version of the analogue measured biopotential signal and the analogue reference signal. The system also includes a first digital filter unit comprising a cascaded integrator-comb filter configured to provide a first digital filtered version of the digital measured biopotential signal and the reference signal, and a second digital filter unit configured to calculate a digital motion artifact estimate based on the first digital filtered version signals..
Imec Vzw


08/06/15
20150216219 

Sweetness enhancers, compositions thereof, and methods for use


Disclosed herein are sweetener compositions comprising at least one sweetener and at least one sweetness enhancer chosen from terpenes (such as sesquiterpenes, diterpenes, and triterpenes), flavonoids, amino acids, proteins, polyols, other known natural sweeteners (such as cinnamaldehydes, selligueians, hematoxylins), secodammarane glycosides, and analogues thereof, wherein the at least one sweetness enhancer is present in the composition in an amount at or below the sweetness detection threshold level of the sweetness ehancer, and the at least one sweetener and the at least one sweetness enhancer are different. Also disclosed herein are methods for enhancing sweetness of a composition, comprising combining at least one sweetener and at least one sweetness enhancer chosen from terpenes (such as sesquiterpenes, diterpenes, and triterpenes), flavonoids, amino acids, proteins, polyols, other known natural sweeteners (such as cinnamaldehydes, selligueians, hematoxylins), secodammarane glycosides, and analogues thereof, wherein the at least one sweetness enhancer is present in the composition in an amount at or below the sweetness detection threshold level of the at least one sweetness enhancer, and the at least one sweetener and the at least one sweetness enhancer are different..
The Coca-cola Company


07/30/15
20150215141 

Method and device to control the gain of a radio receiver


An automatic gain control (agc) method and system for a radio receiver are proposed in which the acg comprises two agc loops; a first loop controlling signal gain in the analogue portion of the radio receiver, a second loop controlling gain in the digital domain after digitization of the received signal. The analogue agc loop has a slower response time than the digital agc loop.
Ericsson Modems Sa


07/30/15
20150212078 

Pro-substrates for live cell applications


Provided are pro-substrates useful in assays of living cells. The pro-substrates can be used to detect the presence or absence of enzymes, such as luciferase, in living cells.
Promega Corporation


07/30/15
20150210748 

Protease stabilized acylated insulin analogues


Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain b25h and a14e or a14h..
Novo Nordisk A/s


07/30/15
20150210747 

Protease stabilized acylated insulin analogues


Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain b25h and a14e or a14h..
Novo Nordisk A/s


07/30/15
20150210745 

Double-acylated glp-1 derivatives with a linker


The invention relates to a derivative of a glp-1 analogue, which analogue comprises a first k residue at a position corresponding to position 18 of glp-1(7-37) (seq id no: 1), a second k residue at another position, and a maximum of twelve amino acid changes as compared to glp-1(7-37); which derivative comprises two protracting moieties attached to said first and second k residue, respectively, via a linker, wherein the protracting moiety is selected from hooc—(ch2)x-co—*, and chem. 1: hooc—c6h4-0-(ch2)y-co—*, chem.
Novo Nordisk A/s


07/30/15
20150210744 

Glucagon analogues


The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation..
Zealand Pharma A/s


07/30/15
20150210714 

Novel rapamycin analogue


There is provided inter alia a compound of formula (i) or a pharmaceutically acceptable salt thereof and its use in therapy.. .
Buck Institute For Research On Aging


07/30/15
20150210653 

Analogues of porphyrins, their preparation and use thereof


The present invention relates to compound of formula (i), their method of preparation and use thereof in particular in the fields of optoelectronic, photonic, photovoltaics and biology.. .
Université D'aix-marseille


07/30/15
20150209411 

Treatment of osteoarthritis with incretin hormones or analogues thereof


The present invention relates to the use of the incretin hormones glucagon-like peptide-1 or glp-1 and glucose-dependent insulinotropic polypeptide or gip, or of analogues thereof, in particular the analogues resistant to dipeptidyl peptidase iv, in the treatment of osteoarthritis, in particular for inhibiting or slowing down cartilage destruction.. .
Universite Pierre Et Marie Curie (paris6)


07/23/15
20150203524 

New polyphosphate synthesis


The subject of the invention is a new method of the synthesis of polyphosphate analogues, such as nucleosides, oligonucleotides, carbohydrates, peptides and proteins, which are of biological importance and are used in organic chemistry, molecular biology and biotechnology. Polyphosphate analogues, including in particular nucleoside 5′-triphosphates, display high biological activity and are responsible for the provision and storage of energy in live organisms.
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk


07/23/15
20150203442 

Anthraquinone analogs and methods of making and using thereof


Rhein analogues that exhibit anti-proliferative activity, particular against cancer cells, are described herein. In some embodiments, the compounds contain a flat or planar ring system.
Children's Healthcare Of Atlanta


07/16/15
20150197800 

Massive parallel decoding dna and rna


This invention provides methods for attaching a nucleic acid to a solid surface and for sequencing nucleic acid by detecting the identity of each nucleotide analogue after the nucleotide analogue is incorporated into a growing strand of dna in a polymerase reaction. The invention also provides nucleotide analogues which comprise unique labels attached to the nucleotide analogue through a cleavable linker, and a cleavable chemical group to cap the —oh group at the 3′-position of the deoxyribose..
The Trustees Of Columbia University In The City Of New York


07/16/15
20150197550 

Therapeutic uses of dogfish glucagon and analogues thereof


The present invention relates to peptides of 12 to 50 amino acids in length which incorporate the amino acid sequence mdnrrak for use in the treatment of obesity, type-2 diabetes or metabolic syndrome.. .
University Of Ulster


07/16/15
20150197539 

Novel chartreusin analogues


The present invention relates to novel chartreusin analogues of formula (i), pharmaceutical compositions comprising the same and to their use for the treatment of cancer and other diseases.. .
Leibniz-institut Für Naturstoff-forschung Und Infektionsbiologie, Hans Knöll Institut


07/16/15
20150197522 

Inauhzin analogues that induce p53, inhibit cell growth, and have antitumor activity


Inauhzin (inz) was identified as a novel p53 activator, which selectively and efficiently suppressing tumor growth without displaying genotoxicity and with little toxicity to normal cells. A panel of inz analogs were synthesized and evaluated their ability to induce cellular p53 and to inhibit cell growth in cell-based assays.
Indiana University Research And Technology Corp.


07/16/15
20150196569 

Pharmaceutical compositions for the treatment of inner ear disorders


The present invention provides compositions containing (i) a pharmaceutically active agent selected from a group consisting of an arylcycloalkyamine or a derivative, analogue or pharmaceutically active salt thereof, and (ii) a biocompatible polymer or a combination of biocompatible polymers. These compositions or medicaments containing these compositions may be used for the prevention and/or treatment of inner ear diseases, e.g.
Auris Medical Ag


07/16/15
20150196249 

Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine


The present invention generally relates to compositions comprising anesthesia-reversing agents which facilitate or increase the time of awakening or reverse the effects of general anesthesia-induced unconsciousness. In some embodiments, the anesthesia reversing agent can be selected from any or a combination of methylphenidate (mph), amphetamine, modafinil, amantadine, caffeine, or analogues or derivatives thereof.
The General Hospital Corporation


07/09/15
20150195792 

Thermal noise floor estimation robustness via multi-carrier combining


The present invention provides methods and arrangements 300 which are configured to determine a noise rise estimates in a radio access node of a radio network system 100 supporting multi-carrier high-speed packet access transmission of user radio traffic between a radio access node and one or more user equipments. The arrangement is provided with a combiner combining the estimated thermal noise power floors of all carriers of a set of carriers sharing the same antenna branch, into a single thermal noise power floor estimate, valid for all carriers in said set of carriers sharing the same analogue signal path.
Telefonaktiebolaget L M Ericsson (publ)


07/09/15
20150194975 

Analogue-to-digital converter


An analogue-to-digital converter for converting an analogue input signal into a digital output signal, the analogue-to-digital converter including two conversion paths, each configured to receive a version of the analogue input signal and convert it into a digital bit stream, a first feedback loop configured to provide feed-back, to both paths, that is indicative of a difference between the digital bit streams output by the two paths, and a second feedback loop configured to feed-back, to both paths, that is indicative of an average of the digital bit streams output by the two paths.. .
Cambridge Silicon Radio Limited


07/09/15
20150194616 

Tetradentate platinum and palladium complex emitters containing phenyl-pyrazole and its analogues


A phosphorescent emitter or delayed fluorescent and phosphorescent emitters represented by formula 1 or formula ii, where m is platiunum or palladium.. .

07/09/15
20150191503 

Organic compounds


This invention relates to sphingoglycolipid analogues, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.. .
Callaghan Innovation Research Limited


07/09/15
20150191501 

Advanced glycation end product analogues


Disclosed are processes for the production of composition comprising one or more fructose amino acids, said process comprising the steps of: (a) providing plant material derived from a botanical source selected from plants of the families solanaceae, compositae, (asteraceae), guttiferae, umbelliferae, papaveraceae, vitidaceae or acanthaceae; (b) extracting one or more fructose amino acid(s) from said plant material; and optionally (c) detecting the presence and/or measuring the amount of said fructose amino acid(s) in the extract of step (b).. .
Phytoquest Limited


07/09/15
20150190472 

Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ace2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation


The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogues, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-ii converting enzyme (ace2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide.
Universidad De Chile


07/09/15
20150190461 

Dosing instructions for endotoxin-binding lipopeptides


The invention relates to an endotoxin-binding lipopeptide selected from the group consisting of polymyxins, polymyxin derivatives, polymyxin analogues, prodrugs thereof and pharmaceutically acceptable salts thereof, and also relates to a preparation for parenteral administration comprising a lipopeptide of this type, for prophylaxis or for treatment of diseases and conditions caused by endotoxemia, by i) parenterally administering a bolus of the lipopeptide to achieve a lipopeptide serum concentration of 0.01 μg/ml to 0.8 μg/ml and ii) maintaining this lipopeptide serum concentration by parenterally administering the lipopeptide over a specifiable period of time.. .
Zentrum Für Biomedizinische Technologie Der Donau- Universität Krems


07/09/15
20150190385 

Thiazolidinedione analogues


The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes.. .
Metabolic Solutions Development Company, Llc


07/02/15
20150185039 

Contact-analogue display, in particular of a lane change


A method is disclosed for the contact-analogue display of a navigation instruction for a driving maneuver, particularly a lane change, of a vehicle, wherein the driving maneuver can be carried out at any point of a cohesive driving route of a road. The method includes: contact-analogue stationary displaying of the instruction at the beginning of the driving route for a first distance traveled by the vehicle; adapting the contact-analogue display of the instruction to the change of position of the vehicle, so that the instruction changes its position corresponding to the change of position of the vehicle, for a second distance traveled by the vehicle; and contact-analogue stationary displaying of the instruction at the end of the driving route, for a third distance traveled by the vehicle..
Bayerische Motoren Werke Aktiengesellschaft


07/02/15
20150184239 

Polymerases for nucleotide analogue incorporation


Compositions that include polymerases with features for improving entry of nucleotide analogues into active site regions and for coordinating with the nucleotide analogues in the active site region are provided. Methods of making the polymerases and of using the polymerases in sequencing and dna replication and amplification as well as kinetic models of polymerase activity and computer-implemented methods of using the models are also provided..
Pacific Biosciences Of California, Inc.


07/02/15
20150183847 

Protein and protein conjugate for diabetes treatment, and applications thereof


The present invention relates to the field of biopharmaceutics, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is glp-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a gip receptor binding polypeptide or an analogue thereof.
Adda Biotech Inc.


07/02/15
20150183757 

Method of producing beraprost


An improved method is described for making single isomers of synthetic benzoprostacyclin analogue compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds..
Lung Biotechnology Inc.


07/02/15
20150183721 

Amino-alcohol analogues and uses thereof


This invention relates to amino-alcohol analogues and uses thereof in the treatment of diseases and disorders such as cancer, neurodegenerative and metabolic diseases and genetic storage diseases.. .
Yissum Research Development Company Of The Hebrew University Of Jerusalem,


07/02/15
20150183205 

Method for optimising flexographic negatives


The invention provides an improved method of imaging analogue flexographic liquid and sheet printing plates. Specifically it involves adding colour or greyscale to some of the clear parts of negatives used to make flexographic plates.

07/02/15
20150182594 

Novel glucagon analogues


The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s


06/25/15
20150180650 

Synchronisation for transmit and receive symbols of all-digital receiver


A synchronisation method and device for transmit and receive symbols of an all-digital receiver. The method comprises the steps of: after receiving a sampling signal sent by a baseband processing chip, the clock signal of which is provided by a second clock source, a digital signal processor (dsp), the clock signal of which is provided by a first clock source, measuring a phase shift between a local sampling symbol and an air interface symbol, and acquiring the phase shift amount; according to the phase shift amount, adjusting a sampling opportunity for the sampling of a digital-analogue/analogue-digital converter; and when the sampling opportunity for the sampling of the digital-analogue/analogue-digital converter has been adjusted, adjusting an interface clock for data transmitting and receiving of the dsp so as to enable the data transmitting and receiving of the dsp to be synchronised with the sampling..
Hytera Communications Corp., Ltd.


06/25/15
20150180496 

Phase estimator


A phase estimator comprising a first input terminal configured to receive a first analogue input signal; a second input terminal configured to receive a second analogue input signal, wherein the second analogue input signal is 90° out of phase with the first analogue input signal. The phase estimator is configured to provide a digital word representative of the phase of the first analogue input signal and the second analogue input signal.
Nxp B.v.


06/25/15
20150180495 

Converter arrangement and converting an analogue input signal into a digital output signal


The invention relates to an arrangement and a method for the identification of parameters in a nonlinear model of an analog-to-digital converter (adc 17) and the use of this information to reduce the nonlinear distortions of the adc. A parameter estimator determines an ad parameter vector pad which describes the nonlinearities of the adc (17).

06/25/15
20150175665 

Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal


There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide, pharmaceutical compositions containing said compounds, and the use of said compounds as gip-receptor agonists or antagonists for treatment of gip-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.. .
Ipsen Pharma S.a.s.


06/25/15
20150175645 

Nicotinamide riboside and analogues thereof


Provided herein are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing.
Glaxosmithkline Llc


06/25/15
20150175587 

Synthesis of epothilones, intermediates thereto and analogues thereof


As described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (i) and provides methods of treating cancer comprising administering a compound of formula (i)..

06/25/15
20150174232 

Composition and uses thereof


An immunogenic composition comprising the nm-acp protein or an immunogenic part thereof or an analogue thereof, wherein the composition is capable of eliciting an immune response when administered to a human or non-human animal.. .
University Of Southampton


06/25/15
20150174095 

Pharmaceutical compositions for the treatment of visual system disorders


The present invention relates to pharmaceutical compositions comprising d-serine transporter inhibitors which are proline analogues and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.. .
Allergan, Inc.


06/25/15
20150173683 

System and acquisition of biopotential signals with motion artifact reduction


A biopotential signal acquisition system including an analogue readout unit configured to receive an analogue biopotential signal, which may be acquired from at least one electrode attached to a body; and to extract an analogue measured biopotential signal and an analogue reference signal. The system also includes an adc unit configured to provide a digital version of the analogue measured biopotential signal and the analogue reference signal, a digital filter unit configured to calculate a digital motion artifact estimate based on the digital version of the measured biopotential signal and the reference signal.
Imec Vzw


06/18/15
20150168917 

Control an analogue display fitted to a timepiece movement


In a backward direction, in accelerated mode, during a second period following the first period, before the periodic actuation wheel set is driven in a position of its area of actuation.. .

06/18/15
20150166990 

Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues


Disclosed herein are double-stranded rna nucleic acid molecules, which include at least one pyrazolotriazine nucleotide analogue and have been modified to exhibit one of the following, increased on-target activity, increased target specificity, enhanced nuclease stability, reduced off target activity and/or reduced immunogenicity when compared to an unmodified or similarly modified dsrna; pharmaceutical compositions comprising such molecules and methods of use thereof in therapy.. .
Qbi Enterprises Ltd.


06/18/15
20150166625 

Exendin-4 peptide analogues


The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. .
Sanofi


06/18/15
20150166513 

Heterocyclyl pyrimidine analogues as tyk2 inhibitors


Wherein r, r1, x1 to x5 have the meaning as cited in the description and the claims. Said compounds are useful as tyk2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases.

06/18/15
20150165139 

Intranasal administration


Intranasal administration of proteins, such as insulin and insulin analogues, in particular immunogenic proteins to the upper posterior region of a nasal cavity of a subject, and in particular the olfactory bulb region.. .
Optinose As


06/18/15
20150165046 

Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators


The present invention relates to stable compositions comprising a sphingosine 1 phosphate (s1p) receptor modulator, suitable for use as a dosage form. The s1p receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g.
Novartis Ag


06/18/15
20150164998 

Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and treatment of diabetes


The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterised by a prolonged, flat, truly peakless course of glucose concentration vs.
Instytut Biotechnologii I Antybiotykow


06/18/15
20150164996 

Non-acylated exendin-4 peptide analogues


The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.. .
Sanofi


06/18/15
20150164995 

Exendin-4 peptide analogues as dual glp-1/gip agonists


The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. .
Sanofi


06/18/15
20150164992 

Methods and compositions for promoting organ growth and development


Methods and compositions are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or foetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (csf-1), precursor, variant, analogue, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (csf-1), precursor, variant, analogue, derivative thereof, or combinations thereof..
Kintan Pty Ltd.


06/18/15
20150164921 

Chemoprevention of colorectal cancer


In the present invention, a new combination is disclosed comprising (i) 5-aminosalicylic acid (5-asa) or a derivative thereof, or a pharmacologically acceptable salt thereof, and (ii) a group d vitamin, a derivative thereof, a metabolite or analogue, for use in the prevention and/or treatment of colorectal cancer (crc). A further aspect of the invention is directed to pharmaceutical compositions comprising said combination together with at least one physiologically acceptable excipient and the use thereof in the prevention and/or in the treatment of the colorectal cancer..
Lga Biotecnologie S.r.l.


06/18/15
20150164826 

Dosage forms and related therapies


This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.. .
Philera New Zealand Limited


06/18/15
20150164107 

Frozen dessert mixes using pulse protein products


Pulse protein products having a protein content of at least about 60 wt % (n×6.25) d.b., preferably at least about 90 wt %, and being soluble at ph values of less than about 4.4 and heat stable at such ph values, or alternatively adjusted in ph to a ph of about 6 to about 8 and further processed by drying the product, recovering and drying any precipitated pulse protein material, heat treating and then drying the product, or heat treating the product and recovering and drying any precipitated pulse protein material are used to provide, at least in part, the protein component of a dairy analogue, dairy alternative or plant/dairy blend frozen dessert mix.. .
Burcon Nutrascience (mb) Corp.


06/11/15
20150158864 

Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyr-rolo[2,3-d]pyridinyl acrylamides


The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting janus kinase (jak).
Pfizer Inc.


06/11/15
20150158841 

Curcumin analogs


Provided herein are curcumin analogues that are able to interact with amyloid β (aβ) and to attenuate the copper-induced crosslinking of aβ. Also provided herein are methods of using the compounds in the treatment of alzheimer's disease or a related disorder..
The General Hospital Corporation


06/11/15
20150157642 

Cosmetic changing the appearance of eyes


The current application is directed to cosmetic methods for changing the appearance of eyes by causing a retraction of the eyelids so that the eyes appear to be more open and have a wider appearance. Various methods involve application of one or more prostaglandins, synthetic prostaglandins, including synthetic prostaglandin f, and synthetic prostaglandin analogues, to eyelids, which results in contraction of eyelid muscles and a wider, more open appearance of the eyes..

06/11/15
20150157580 

Methods of regulating cannabinoid receptor activity-related disorders and diseases


This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (cb) receptor activity-related disorders and disease, such as dysregulated cb receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by cb receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by cb receptor activity..
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services


06/04/15
20150153712 

Method for displaying a trend over a timing operation and associated timepiece


Portable timepiece including an hour hand and a minute hand for the current time display, rotating about a central wheel facing a bezel, and also a chronograph module, wherein the timepiece further includes a first analogue trend indicator relating to a measured time interval.. .
Eta Sa Manufacture Horlogere Suisse


06/04/15
20150153344 

Coelenterazine analogues and coelenteramide analogues


Coelenterazine analogues with different luminescence properties from conventional ones and coelenteramide analogues with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogues modified at the 8-position of coelenterazine and coelenteramide analogues modified at the 2- or 3-position of coelenteramide..
National University Corporation Tokyo Medical And Dental University


06/04/15
20150150968 

Use of cd28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections


The invention relates to the use of monoclonal antibodies which are specific for cd28 and activate the t lymphocytes of several up to all subgroups without the occupation of an antigen receptor of the t lymphocytes and which therefor activate said lymphocytes in an antigen unspecific manner or the invention relates to the use of an analogue thereof for producing a pharmaceutical composition in the form of a preparation or a preparation packet for treating virus infections in humans or lower warm-blooded animals having infected t lymphocytes. The pharmaceutical composition additionally contains a virus inhibitor.
Theramab Llc


06/04/15
20150150847 

Use of n-acetyl-5-methoxytryptamine or analogues thereof, for promoting the mechanism of implantation of the embryo and related compositions and culture media


The present invention refers to the use of n-acetyl-5-methoxytryptamine (melatonin) and/or an analogue thereof, for use in the medical or veterinary field in the assisted reproduction for promoting the mechanism of implantation of the embryo, and in particular for the prevention of implantation failure into the uterus, by topical administration of an effective amount in a mammalian subject female in need of such treatment, and related compositions, culture media and medical devices.. .
Ares Trading S.a.


06/04/15
20150150483 

Device, method and software for measuring exhalation capacity


Measurement device (1) for measuring the exhale capacity of a patient, includes a main body (2) with a through hole (3) with a blowing device (17) which has a rotation device (20) which is put in rotary motion through blowing, with a rotary speed depending on the intensity of the blowing, and the rotation of which is sensed by an optical sensor (6). The measuring device includes a cable (11) which is connected to the main body of the measurement device, and with a free end (11b) which is arranged to be connected to an audio input of a handheld general purpose computer unit (14), and in that the measurement device is arranged to, to the handheld computer unit, continuously deliver an analogue electric signal which carries information about rotary speed or air flow.
Pond Health Care Innovation Ab


05/28/15
20150148524 

Amino acid analogues and methods for their synthesis


A method for the synthesis of an amino acid analogue or a salt, solvate, derivative, isomer or tautomer thereof comprising the steps of: (i) subjecting an amino acid containing a metathesisable group to metathesis with a compound containing a complementary metathesisable group of formula (i) or (ii): (formulae (i), (ii)) wherein r1 and r2 are independently selected from h and substituted or unsubstituted c1 to c4 alkyl; each r3 is either absent or independently selected from a heteroatom, a substituted or unsubstituted c1 to c20 alkyl, and a substituted or unsubstituted c1 to c20 alkyl group interrupted by one or more heteroatoms; and each x is independently selected from h and an effector molecule; in the presence of a reagent to catalyse the metathesis to form a dicarba bridge between the amino acid containing a metathesisable group and the compound containing a complementary metathesisable group; and (ii) reducing the dicarba bridge to form a saturated dicarba bridge, wherein the reagent used to catalyse step (i) also catalyses step (ii).. .
Monash University


05/28/15
20150148417 

Synthesis and biological studies of an isomeric mixture of (e/z) isoxylitones and its analogues


The invention relates to an anti-epileptic isoxylitone, 2,2′-(3,5,5-trimethyl-2-cylohexen-1-ylidene)acetic acid.. .



Popular terms: [SEARCH]

Analogue topics: Carbon Dioxide, Amino Acid, Radio Signal, Inorganic Compounds, Hydrogen Production From Water, Electrolysis, Semiconductor, High Energy, Semiconductor Material, Transmitter, Synchronization, Concurrent, Surfactant, Hyperglycemia, Pharmaceutically Acceptable Salt

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Analogue for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Analogue with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.6033

4457

3 - 0 - 101